false 0000021076 0000021076 2024-11-20 2024-11-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 20, 2024

THE CLOROX COMPANY
(Exact name of registrant as specified in its charter)

 
Delaware 1-07151 31-0595760
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation)   Identification No.)

1221 Broadway, Oakland, California 94612-1888
(Address of principal executive offices) (Zip code)

(510) 271-7000
(Registrant's telephone number, including area code)

Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 Under the Securities Act (17 CFR 230.425)
   
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading
Symbol(s)
Name of each exchange on which registered
Common Stock - $1.00 par value CLX New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company     

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

  (a) On November 20, 2024, The Clorox Company (the “Company”) held its virtual annual meeting of shareholders.
     
  (b) The shareholders (1) elected all of the Company’s nominees for director, (2) approved the compensation of the Company’s named executive officers on an advisory basis, and (3) ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2025.

The final voting results on each of the matters submitted to a vote are as follows:

  1. Election of Directors:
    Number of Votes
    For Against   Abstain   Broker Non-Votes
Stephen B. Bratspies   88,574,185 420,571   210,942   17,145,925
Pierre R. Breber   88,583,063 415,714   206,922   17,145,925
Julia Denman   88,472,706 543,421   189,572   17,145,925
Spencer C. Fleischer   87,205,016 1,796,214   204,469   17,145,925
Esther Lee   85,346,195 3,664,298   195,206   17,145,925
A.D. David Mackay   88,390,870 612,443   202,385   17,145,925
Stephanie Plaines   88,432,195 587,490   186,014   17,145,925
Linda Rendle   84,229,786 4,419,727   556,185   17,145,925
Matthew J. Shattock   87,379,925 1,623,635   202,138   17,145,925
Russell J. Weiner   88,356,468 636,204   213,027   17,145,925
Christopher J. Williams   87,694,853 1,305,769   205,076   17,145,925
  2. Advisory Vote on the Approval of Named Executive Officers Compensation:
Number of Votes
For   Against   Abstain   Broker Non-Votes
83,241,298   5,474,458   489,942   17,145,925
  3. Ratification of the selection of Ernst & Young LLP as the Company’s independent auditor for 2025.
Number of Votes
For   Against   Abstain   Broker Non-Votes
101,119,064   4,974,815   257,744   0

2

 

Item 8.01 Other Events.

On November 20, 2024, the shareholders of the Company elected Stephen B. Bratspies and Pierre R. Breber to the Board of Directors of the Company. A press release announcing the election of Messrs. Bratspies and Breber is filed as Exhibit 99.1 and is incorporated herein in its entirety.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

See the Exhibit Index below.

EXHIBIT INDEX

Exhibit   Description
     
99.1   Press Release dated November 20, 2024 of The Clorox Company
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

3

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    THE CLOROX COMPANY
 
Date:  November 21, 2024 By:  /s/ Angela Hilt
      Angela Hilt
      Executive Vice President – Chief Legal Officer
and Corporate Secretary

 

4